(marketscreener.com) BEACON Trial of BEAM-101 in Sickle Cell Disease Ongoing with Data from Multiple Patients Expected in 2024; Expansion Phase Initiation Expected in 2023 First Patient Dosing in BEAM-201 Trial in Patients with T-ALL/T-LL Expected by Mid-2023 Regulatory Submissions Planned for BEAM-301 by Late 2023/Early 2024 and BEAM-302 in Early 2024 North...https//www.marketscreener.com/quote/stock/BEAM-THERAPEUTICS-INC-102685993/news/Beam-Therapeutics-Reports-Progress-Across-Base-Editing-Portfolio-and-Outlines-Key-Anticipated-Milest-42691060/?utm_medium=RSS&utm_content=20230109

Budget 2023 The health sector has been allocated Rs 89,155 crore in the Union Budget 2023-24, a hike of around 13 per cent over Rs 79,145 crore allocated in 2022-23, with the government also announcing a mission to eliminate sickle cell anaemia by 2047.

Research in baboons suggests that misfolded proteins linked to Parkinson’s disease can travel from the brain to gut and vice versa – with both routes causing equal amounts of brain cell death

Treatments involve adding a new gene, or using CRISPR to edit one.

Athersys is trying to succeed where many other biotechs have failed The stem cell therapy industry. Here's why they think they can.

MONTREAL, Nov. 08, 2022 (GLOBE NEWSWIRE) — ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and rejuvenation, announced today that its proprietary ECT-001 Cell Therapy has been administered to 100 patients. ECT-001 Cell Therapy is an investigational UM171-expanded cord blood cell therapy being evaluated in trials across multiple adult and pediatric hematological […]

(marketscreener.com) ― Selected 12mg as the dose for next cohort in the Phase 1b trial of FTX-6058 in sickle cell disease ― ― Presented 96-week data from the Phase 2 ReDUX4 trial open label extension study at World Muscle Society conference ― ― Completed equity raise of approximately $80.8 million in net proceeds; Updated cash...https//www.marketscreener.com/quote/stock/FULCRUM-THERAPEUTICS-INC-62037838/news/Fulcrum-Therapeutics-Announces-Recent-Business-Highlights-and-Third-Quarter-2022-Financial-Results-42240611/?utm_medium=RSS&utm_content=20221108

(marketscreener.com) SITC 2022 Abstract 645 Phase I Study of Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine and Pepinemab/Trastuzumab in Patients with Metastatic HER2-Positive Breast Cancer ...https//www.marketscreener.com/quote/stock/VACCINEX-INC-45256990/news/Vaccinex-Phase-I-Study-of-Adoptive-T-Cell-Therapy-Following-HER2-Pulsed-Dendritic-Cell-Vaccine-and-42271853/?utm_medium=RSS&utm_content=20221110

Research reveals a promising stem cell approach to correct photoreceptor cell degeneration, which underlies several forms of visual decline and blindness.

(marketscreener.com) 2021 Annual Report Fueledby Connections A leader in the field of cellular metabolism pioneering therapies for genetically defined diseases Dianaba, Sickle Cell Disease Ryan,...https//www.marketscreener.com/quote/stock/AGIOS-PHARMACEUTICALS-IN-13709228/news/Agios-Pharmaceuticals-View-the-2021-Annual-Report-42514875/?utm_medium=RSS&utm_content=20221209

MONTREAL, Nov. 08, 2022 (GLOBE NEWSWIRE) — ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and rejuvenation, announced today that its proprietary ECT-001 Cell Therapy has been administered to 100 patients. ECT-001 Cell Therapy is an investigational UM171-expanded cord blood cell therapy being evaluated in trials across multiple adult and pediatric hematological […]

(marketscreener.com) Dosed second patient with EDIT-301 in the Phase 1/2 RUBY trial for sickle cell disease On track to announce initial preliminary clinical data from RUBY trial by year-end Completed cell editing and currently scheduling first patient dosing with EDIT-301 in Phase 1/2 EDITHAL trial for TDT Company to provide a clinical update on the Phase 1/2...https//www.marketscreener.com/quote/stock/EDITAS-MEDICINE-INC-26123639/news/Editas-Medicine-Announces-Third-Quarter-2022-Results-and-Business-Updates-42175871/?utm_medium=RSS&utm_content=20221102

(marketscreener.com) MALVERN, Pa., Feb. 17, 2023 -- Ocugen, Inc. , a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the Company’s Chief Scientific Officer, Arun Upadhyay, Ph.D., will participate in the Retinal Vascular Disease Drug Development Summit at the Hilton...https//www.marketscreener.com/quote/stock/OCUGEN-INC-19157135/news/Ocugen-to-Present-at-Retinal-Vascular-Disease-Drug-Development-Summit-43019137/?utm_medium=RSS&utm_content=20230217

The demand for blood to treat sickle cell disease has risen by over two thirds in the last five years, a report suggests. 

The demand for blood to treat sickle cell disease has risen by over two thirds in the last five years, a report suggests. 

(marketscreener.com) Updated data from the phase 2 clinical trial of CAN-2409 in non-small cell lung cancer showing disease control rate of 77 percent in patients entering the study with progressive disease, translating into preliminary evidence of improved progression-free survivalHighlighted effects of a single injection of CAN-3110 in recurrent high-grade glioma ...https//www.marketscreener.com/quote/stock/CANDEL-THERAPEUTICS-INC-125090831/news/Candel-Therapeutics-R-D-Day-Presentations-Spotlight-its-Advanced-Pipeline-and-Capabilities-to-Develo-42489874/?utm_medium=RSS&utm_content=20221206

Commentary Curing HIV and sickle cell disease with gene-based therapy falls short if vulnerable populations in Africa are excluded.

Development could serve as a catalyst to turn lethal disease into chronic, stable disease.

Blood donations are now needed every day to treat people with sickle cell disease.

Understanding when and why a cell dies is fundamental to the study of human development, disease, and aging. For neurodegenerative diseases such as Lou Gehrig’s disease, Alzheimer’s, ...

(marketscreener.com) Allogeneic off-the-shelf iNKT cell therapy, agenT-797, alone and in combination with pembro/nivo reports early clinical activity in solid tumors, with 27% and 66% of patients, respectively, had a reduction of target and non-target lesions or disease stabilizationFirst immune cell therapy to show a survival benefit in patients with viral acute...https//www.marketscreener.com/quote/stock/MINK-THERAPEUTICS-INC-128249930/news/MiNK-Presents-Clinical-Data-at-SITC-2022-Showcasing-iNKT-Cell-Therapy-Pipeline-42271649/?utm_medium=RSS&utm_content=20221110

The demand for blood to treat sickle cell disease has risen by over two thirds in the last five years, a report suggests. 

The demand for blood to treat sickle cell disease has risen by over two thirds in the last five years, a report suggests. 

ProKidney initiated at equal weight at Morgan Stanley on cell therapy for kidney disease

(marketscreener.com) Dima, Tristan, & Stephanie LIVING WITH SICKLE CELL DISEASE Corporate Effectiveness Addressing ESG & Long-term Sustainability April...https//www.marketscreener.com/quote/stock/EDITAS-MEDICINE-INC-26123639/news/Editas-Medicine-Corporate-Effectiveness-Report-April-2023-43496530/?utm_medium=RSS&utm_content=20230414

The demand for blood to treat sickle cell disease has risen by over two thirds in the last five years, a report suggests. 

The demand for blood to treat sickle cell disease has risen by over two thirds in the last five years, a report suggests. 

The demand for blood to treat sickle cell disease has risen by over two thirds in the last five years, a report suggests. 

Two people with beta thalassaemia and one with sickle cell disease no longer need blood transfusions after their blood stem cells were gene edited and put back in their bodies

A former supervisory correctional officer ordered detainee abuse as well as allowed a white supremacist assault of two Black pretrial inmates.

(marketscreener.com) BEACON Trial of BEAM-101 in Sickle Cell Disease Ongoing with Data from Multiple Patients Expected in 2024; Expansion Phase Initiation Expected in 2023 First Patient Dosing in BEAM-201 Trial in Patients with T-ALL/T-LL Expected by Mid-2023 Regulatory Submissions Planned for BEAM-301 by Late 2023/Early 2024 and BEAM-302 in Early 2024 ...https//www.marketscreener.com/quote/stock/BEAM-THERAPEUTICS-INC-102685993/news/Beam-Therapeutics-Reports-Progress-Across-Base-Editing-Portfolio-and-Outlines-Key-Anticipated-Milest-42691061/?utm_medium=RSS&utm_content=20230109

Demand is at record levels for blood to help people with the disease that mostly affects black people.

An international team of researchers lays the foundation to examine how extracellular RNA and its carrier proteins found in bodily fluids function in a healthy as well as a diseased setting, potentially providing a means to accurately implement early detection and monitor disease processes.

(marketscreener.com) Company Receives First Major Purchase Order in Saudi ArabiaTORRANCE, Calif., Nov. 17, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. , a leader in sickle cell disease treatment, announced today that it has been issued a Registration Certificate from the Registration Committee for Pharmaceutical Companies & their Products of the Qatar...https//www.marketscreener.com/quote/stock/EMMAUS-LIFE-SCIENCES-INC-120797573/news/Emmaus-Life-Sciences-Receives-Endari-Marketing-Authorization-from-the-Qatar-Ministry-of-Public-Heal-42345524/?utm_medium=RSS&utm_content=20221117

Companies investigate how therapies including Crispr might treat a debilitating genetic disease

A clearer understanding about the markers and drivers of cancer cell proliferation has emerged from research that identifies new opportunities to overcome convergence with complex enzymes, known as kinases. The work paves the way for new approaches to study the molecular drivers of disease states such as cancer.

Some people who have long lived with the disease say they worry about living as a healthy person, while others worry about the obstacles to getting treatment.

Demand for blood donations to treat the disease has risen by 67 per cent over the past five years

(marketscreener.com) Updated data from the phase 2 clinical trial of CAN-2409 in non-small cell lung cancer showing disease control rate of 77 percent in patients entering the study with progressive disease, translating into preliminary evidence of improved progression-free survivalHighlighted effects of a single injection of CAN-3110 in recurrent high-grade glioma ...https//www.marketscreener.com/quote/stock/CANDEL-THERAPEUTICS-INC-125090831/news/Candel-Therapeutics-R-D-Day-Presentations-Spotlight-its-Advanced-Pipeline-and-Capabilities-to-Develo-42489874/?utm_medium=RSS&utm_content=20221206

Development could serve as a catalyst to turn lethal disease into chronic, stable disease.

2884041 views on Imgur The magic of the Internet

BEACON – New York Blood Center will be holding a blood drive at Beacon High School on Wednesday, November 9 from 730 a.m. to 600 p.m. in honor of Paris Moore. The public is encouraged to attend this drive after 230 p.m. if they are able. Paris graduated from Beacon High School in 2018. He was born with […]

The demand for blood to treat sickle cell disease has risen by over two thirds in the last five years, a report suggests. 

(marketscreener.com) LONDON, Jan. 09, 2023 -- Autolus Therapeutics plc , a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that it has entered into a non-exclusive license agreement with Cabaletta Bio, Inc . The agreement allows Cabaletta to incorporate Autolus’ proprietary RQR8 safety...https//www.marketscreener.com/quote/stock/AUTOLUS-THERAPEUTICS-PLC-44336207/news/Autolus-Therapeutics-Announces-Collaboration-with-Cabaletta-Bio-for-Use-of-Autolus-Safety-Switch-Sy-42691472/?utm_medium=RSS&utm_content=20230109

(marketscreener.com) LONDON, Jan. 09, 2023 -- Autolus Therapeutics plc , a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that it has entered into a non-exclusive license agreement with Cabaletta Bio, Inc . The agreement allows Cabaletta to incorporate Autolus’ proprietary RQR8 safety...https//www.marketscreener.com/quote/stock/AUTOLUS-THERAPEUTICS-PLC-44336207/news/Autolus-Therapeutics-Announces-Collaboration-with-Cabaletta-Bio-for-Use-of-Autolus-Safety-Switch-Sy-42691472/?utm_medium=RSS&utm_content=20230109

The demand for blood to treat sickle cell disease has risen by over two thirds in the last five years, a report suggests. 

(marketscreener.com) Acquisition brings leading sickle cell disease portfolio and pipeline to Pfizer with potential to address critical needs in an underserved patient communityhttps//www.marketscreener.com/quote/stock/PFIZER-INC-23365019/news/Pfizer-Completes-Acquisition-of-Global-Blood-Therapeutics-41933646/?utm_medium=RSS&utm_content=20221005

San Jose, California–(Newsfile Corp. – December 14, 2022) – Wearing custom cleats designed by Sickle Cell 101, scoring a game-changing touchdown, and winning the AFC Special Teams Player Of The Week, all while advocating for sickle cell—that’s Cleveland Browns’ wide receiver Donovan Peoples-Jones courageously supporting sickle cell for the third year in a row through […]

Research reveals a promising stem cell approach to correct photoreceptor cell degeneration, which underlies several forms of visual decline and blindness.

The demand for blood to treat sickle cell disease has risen by over two thirds in the last five years, a report suggests.